The association of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) in unresectable or metastatic BRAF V600E- or V600K-mutated cutaneous melanoma was evaluated in two randomized controlled trials (COMBI-d study and COMBI-v study) [36]. This evidence concerns the gene BRAF and cutaneous melanoma.